title: Platelet activation through the efficacy of aspirin in congenital heart disease patients undergoing transcatheter closure of atrial septal defects or ventricular septal defects.
abstract: OBJECTIVE
  The aim of this study is to compare preoperative and postoperative conditions of GMP-140 concentration, the aggregation and activation of platelets in congenital heart disease patients undergoing transcatheter closure of atrial septal defects (ASDs) or ventricular septal defects (VSDs), and the appropriate dose of aspirin of patients after transcatheter closure.
  
  
  METHODS
  Thirty-two consecutive patients with ASD (n=16) and VSD (n=16), as shown on transthoracic echocardiography and right heart catheter examination, were treated with a percutaneous catheter occlusion. The patients comprised 13 males and 19 females with a mean age of 25.6±9.15. Patients were randomly assigned into two groups within half an hour after ASD or VSD occlusion. Group A cases were treated with 3 mg/kg/day enteric-coated aspirin tablets for 6 months, while patients in group B received 5 mg/kg/day enteric-coated aspirin tablets for 6 months.
  
  
  RESULTS
  The rates of platelet aggregation (PAG) in the immediate postoperative ASD/VSD occlusion were significantly higher than those in the preoperative ASD/VSD occlusion (adenosine diphosphate [ADP]-induced PAG: 64.98%±7.65% vs. 86.33%±6.54%, p<0.05; arachidonic acid [AA]-induced PAG: 62.92%±9.11% vs. 86.96%±6.90%, p<0.05, respectively). After treatment with aspirin, the GMP-140 levels presented a clearly defined downward trend in the immediate postoperative period (3 mg/kg/day aspirin: 18.30±3.42 vs. 13.37±1.80, p<0.05; 5 mg/kg/day aspirin: 18.30±3.42 vs. 13.41±1.60, p<0.05), but no obvious difference was observed considering the GMP-140 levels in the 4 days after occlusion (all p>0.05).
  
  
  CONCLUSIONS
  Our study showed that the GMP-140 serum level and PAG were increased after ASD and VSD occlusion, and patients may have a trend of decreased GMP-140 serum levels after the ASD or VSD occlusion surgeries after the treatment with aspirin. Daily oral administration of 3 and 5 mg/kg/day aspirin can induce a significant decrease in PAG of patients after VSD/ASD occlusion.
authors.affiliation: 1 Department of Cardiovascular Medicine, Southern Medical University , Guangzhou, People's Republic of China .
authors.forename: Gang
authors.initials: G
authors.lastname: Pan
authors.forename: Zhao-Feng
authors.initials: ZF
authors.lastname: Xie
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Sheng-Chun
authors.initials: SC
authors.lastname: Long
authors.forename: Xi-Ping
authors.initials: XP
authors.lastname: Xu
authors.forename: Zhi-Wei
authors.initials: ZW
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage*; D006328:Cardiac Catheterization; D005260:Female; D006344:Heart Septal Defects, Atrial / Q000097:blood / Q000628:therapy; D006345:Heart Septal Defects, Ventricular / Q000097:blood / Q000628:therapy; D006801:Humans; D008297:Male; D019007:P-Selectin / Q000097:blood*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D013997:Time Factors
chemical_list: D019007:P-Selectin; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin